Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rational use of substrate inhibition and enzyme replacement treatments in adult patients with type 1 Gaucher disease
2007-007164-20Phase 3Completed
- Sponsor
- Instituto Aragonés de Ciencias de la Salud
- Start
- Feb 2008
- Modality
- Small Molecules, Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of miglustat and imiglucerase in Gaucher disease type 1 (GD1) (3 arms), sponsored by Instituto Aragonés de Ciencias de la Salud. Primary endpoint: Change in hemoglobin concentration at 1 year. Started Feb 2008; status: completed.
02
Drugs
miglustatimiglucerase
03
Conditions
Gaucher disease type 1 (GD1)
Beyond the preview
Go deeper on 2007-007164-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007164-20.